TY - JOUR
T1 - Giant cell arteritis and polymyalgia rheumatica
T2 - Current challenges and opportunities
AU - Dejaco, Christian
AU - Brouwer, Elisabeth
AU - Mason, Justin C.
AU - Buttgereit, Frank
AU - Matteson, Eric L.
AU - Dasgupta, Bhaskar
N1 - Funding Information:
C.D. declares that he has received consultancy fees and honoraria from AbbVie, Celgene, Lilly, Merck, MSD, Novartis, Pfizer, Roche, Sandoz and UCB, and unrestricted grant support from MSD and Pfizer, and has acted as a consultant and advisory board member for GSK. E.B. declares that she has received consultancy fees from Roche and an unrestricted grant from Janssen. J.M. declares that he has received consultancy fees and honoraria from Novartis and Roche. F.B. declares that he has received consultancy fees, honoraria and travel expenses from Galapagos, Horizon Pharma (formerly Nitec Pharma), Mundipharma and Roche and grant support from Horizon Pharma, and that he has served as co-principal investigator and site investigator in a Mundipharma-sponsored trial in PMR investigating the effects of modified-release prednisone. E.L.M. declares that he has served as coordinating investigator in a Novartis-sponsored PRM trial, as a consultant in a GSK-sponsored PMR trial, as a consultant for Endocyte and GSK and as a site investigator in GCA trials sponsored by Bristol Meyer Squibb, Genentech, GSK and Hoffman-LaRoche, and that he is an author and editor for UpToDate and Paradigm. B.D. declares that he has acted as a consultant and advisory board member for GSK, Merck, Mundipharma, Pfizer, Roche, Servier and Sobi) and that he has received unrestricted grant support from Napp and Roche and honoraria from Merck and UCB.
Publisher Copyright:
© 2017 Macmilan Publishers Limited, part of Springer Nature. All right sreserved.
PY - 2017
Y1 - 2017
N2 - The fields of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) have advanced rapidly resulting in a new understanding of these diseases. Fast-track strategies and improved awareness programmes that prevent irreversible sight loss through early diagnosis and treatment are a notable advance. Ultrasonography and other imaging techniques have been introduced into routine clinical practice and there have been promising reports on the efficacy of biologic agents, particularly IL-6 antagonists such as tocilizumab, in treating these conditions. Along with these developments, which should improve outcomes in patients with GCA and PMR, new questions and unmet needs have emerged; future research should address which pathogenetic mechanisms contribute to the different phases and clinical phenotypes of GCA, what role imaging has in the early diagnosis and monitoring of GCA and PMR, and in which patients and phases of these diseases novel biologic drugs should be used. This article discusses the implications of recent developments in our understanding of GCA and PMR, as well as the unmet needs concerning epidemiology, pathogenesis, imaging and treatment of these diseases.
AB - The fields of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) have advanced rapidly resulting in a new understanding of these diseases. Fast-track strategies and improved awareness programmes that prevent irreversible sight loss through early diagnosis and treatment are a notable advance. Ultrasonography and other imaging techniques have been introduced into routine clinical practice and there have been promising reports on the efficacy of biologic agents, particularly IL-6 antagonists such as tocilizumab, in treating these conditions. Along with these developments, which should improve outcomes in patients with GCA and PMR, new questions and unmet needs have emerged; future research should address which pathogenetic mechanisms contribute to the different phases and clinical phenotypes of GCA, what role imaging has in the early diagnosis and monitoring of GCA and PMR, and in which patients and phases of these diseases novel biologic drugs should be used. This article discusses the implications of recent developments in our understanding of GCA and PMR, as well as the unmet needs concerning epidemiology, pathogenesis, imaging and treatment of these diseases.
UR - http://www.scopus.com/inward/record.url?scp=85030439208&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030439208&partnerID=8YFLogxK
U2 - 10.1038/nrrheum.2017.142
DO - 10.1038/nrrheum.2017.142
M3 - Review article
C2 - 28905861
AN - SCOPUS:85030439208
VL - 13
SP - 578
EP - 592
JO - Nature Reviews Rheumatology
JF - Nature Reviews Rheumatology
SN - 1759-4790
IS - 10
ER -